WO2018044086A3 - 단백질 제제의 면역원성 측정 방법 - Google Patents

단백질 제제의 면역원성 측정 방법 Download PDF

Info

Publication number
WO2018044086A3
WO2018044086A3 PCT/KR2017/009522 KR2017009522W WO2018044086A3 WO 2018044086 A3 WO2018044086 A3 WO 2018044086A3 KR 2017009522 W KR2017009522 W KR 2017009522W WO 2018044086 A3 WO2018044086 A3 WO 2018044086A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
peripheral blood
blood mononuclear
cell
protein
Prior art date
Application number
PCT/KR2017/009522
Other languages
English (en)
French (fr)
Other versions
WO2018044086A2 (ko
Inventor
임옥재
신덕향
Original Assignee
재단법인 목암생명과학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 목암생명과학연구소 filed Critical 재단법인 목암생명과학연구소
Priority to US16/329,403 priority Critical patent/US20190194618A1/en
Publication of WO2018044086A2 publication Critical patent/WO2018044086A2/ko
Publication of WO2018044086A3 publication Critical patent/WO2018044086A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

[요약] 본 발명은 단백질 제제의 면역원성 측정 방법에 관한 것으로서, 다양한 HLA-DRB1 유전형을 갖는 말초혈액단핵구 라이브러리 구축 단계, 유전형별로 말초혈액단핵구의 CD14+ 단핵구 유래의 미성숙 수지상 세포를 측정 대상 단백질 및 GM-CSF, IL-4, TNF-α, IL-1β, IL-6 및 PGE2를 포함하는 배지에서 배양하여 성숙 수지상세포를 제조하는 단계, 유전형별로 말초혈액단핵구에서 CD8+ T세포를 제거하여 CD8+ T세포-제거된 말초혈액단핵구를 제조하는 단계, 상기 성숙 수지상세포와 상기 CD8+ T세포-제거된 말초혈액단핵구를 1:5 내지 1:20의 세포수로 공배양하는 단계 및 상기 공배양으로 증식된 유전형별 CD4+ T세포의 수를 정량하는 단계를 포함함으로써, 개발중인 단백질 제제의 면역원성을 임상 단계 진입 이전에 높은 정확도로 예측하여 단백질 제제 개발 효율을 증대시킬 수 있는 단백질의 면역원성 측정 방법에 관한 것이다. [대표도] 도 4
PCT/KR2017/009522 2016-09-01 2017-08-31 단백질 제제의 면역원성 측정 방법 WO2018044086A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/329,403 US20190194618A1 (en) 2016-09-01 2017-08-31 Method for measuring immunogenicity of protein agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0112817 2016-09-01
KR1020160112817A KR101848641B1 (ko) 2016-09-01 2016-09-01 단백질 제제의 면역원성 측정 방법

Publications (2)

Publication Number Publication Date
WO2018044086A2 WO2018044086A2 (ko) 2018-03-08
WO2018044086A3 true WO2018044086A3 (ko) 2018-08-09

Family

ID=61305293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/009522 WO2018044086A2 (ko) 2016-09-01 2017-08-31 단백질 제제의 면역원성 측정 방법

Country Status (3)

Country Link
US (1) US20190194618A1 (ko)
KR (1) KR101848641B1 (ko)
WO (1) WO2018044086A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109001332A (zh) * 2018-09-06 2018-12-14 河南工业大学 一种食用油脂中tbhq原始添加量的测定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490308B1 (ko) * 2002-02-25 2005-05-17 크레아젠 주식회사 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
WO2008124142A1 (en) * 2007-04-06 2008-10-16 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490308B1 (ko) * 2002-02-25 2005-05-17 크레아젠 주식회사 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
WO2008124142A1 (en) * 2007-04-06 2008-10-16 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAWA, VIBHA ET AL.: "T- cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation", CLINICAL IMMUNOLOGY, vol. 149, 25 September 2013 (2013-09-25), pages 534 - 555, XP028796013 *
KOREN, E. ET AL.: "Clinical Validation of the 'in Silico' Prediction of Immunogenicity of a Human Recombinant Therapeutic Protein", CLINICAL IMMUNOLOGY, vol. 124, 9 May 2007 (2007-05-09), pages 26 - 32, XP022126245 *
SOUTHWOOD, SCOTT ET AL.: "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires", THE JOURNAL OF IMMUNOLOGY, vol. 160, 1998, pages 3363 - 3373, XP055534028 *

Also Published As

Publication number Publication date
US20190194618A1 (en) 2019-06-27
KR20180025738A (ko) 2018-03-09
WO2018044086A2 (ko) 2018-03-08
KR101848641B1 (ko) 2018-04-13

Similar Documents

Publication Publication Date Title
Pachnio et al. Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium
Sibov et al. Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation
Wei et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells
Qi et al. microRNA expression profiling and bioinformatic analysis of dengue virus‑infected peripheral blood mononuclear cells
Larsson et al. Functional and transcriptional profiling of MUTZ‐3, a myeloid cell line acting as a model for dendritic cells
Ureshino et al. Allelic polymorphisms of KIR s and HLA s predict favorable responses to tyrosine kinase inhibitors in CML
JP2015006183A5 (ko)
US9091679B2 (en) Method for stimulating antigen-specific T cell responses using accelerated co-cultured dendritic cells
WO2018044086A3 (ko) 단백질 제제의 면역원성 측정 방법
Liu et al. A numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology
Jia et al. Comparative analysis of lncRNA and mRNA expression profiles between periodontal ligament stem cells and gingival mesenchymal stem cells
GB0609263D0 (en) Method of fetal cell enrichment
WO2015003160A3 (en) Hepatocytes in co-culture and uses thereof
Wu et al. Mesenchymal Stem Cells Immunosuppressed IL‐22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors
Liu et al. Effect of serum choice on replicative senescence in mesenchymal stromal cells
Yu et al. Meta-analysis of associations between interleukin-17 gene polymorphisms and risk of gastric cancer
Nikitina et al. Stem cell-based trophoblast models to unravel the genetic causes of human miscarriages
Diedrichs et al. Enhanced immunomodulation in inflammatory environments favors human cardiac mesenchymal stromal-like cells for allogeneic cell therapies
Wang et al. Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors
Yuan et al. Programmed death ligand 1 negatively regulates inflammatory response of chronic periodontitis
Wufuer et al. Polymorphism of angiotensin converting enzyme gene and natural longevity in the Xinjiang Uygur people: an association study
Lu et al. Mechanism of umbilical cord mesenchymal stem cells in the up-regulation of regulatory T cells by transforming growth factor β1 in systemic lupus erythematosus
Guarneri et al. Glutathione S-transferase M1/T1 genotype and melanoma in a Southern Italian population: a case-control study.
MY190256A (en) Method for manufacturing natural killer t (nkt) cell - stimulating dendritic cell and method for manufacturing cell compostion containing thereof and nkt cell
Liu et al. Advances in Mechanism of HIV-1 Immune Reconstitution Failure: Understanding Lymphocyte Subpopulations and Interventions for Immunological Nonresponders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17847011

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17847011

Country of ref document: EP

Kind code of ref document: A2